Physician profile
Frank C Babb
NPI 1982745832
$11,998.79
in general payments reported to CMS, 2019-2025
25 companies · $1,929 in 2025
The $1,929 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $1,175 · 2021: $1,973 · 2022: $1,848 · 2023: $2,016 · 2024: $1,952 · 2025: $1,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,856 · Education: $40.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,855.59 |
| Education | $40.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,994.26 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $2,900.80 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Mallinckrodt Hospital Products INC. | $1,594.72 | 2020-2025 | Acthar |
| Genentech USA, INC. | $972.91 | 2019-2024 | Xolair |
| Genzyme Corporation | $741.67 | 2021-2025 | |
| Mallinckrodt Enterprises LLC | $306.43 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $254.09 | 2021-2022 | |
| Amarin Pharma, INC. | $234.47 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $180.23 | 2022-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $147.34 | 2019-2020 | |
| Mylan Specialty L.P. | $132.09 | 2023-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $69.11 | 2020 | |
| Verona Pharma, INC. | $68.42 | 2025 | Ohtuvayre |
| Regeneron Pharmaceuticals, INC. | $58.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $58.00 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $57.04 | 2025 | Rexulti |
| Amgen INC. | $41.69 | 2024 | Tezspire |
| Paratek Pharmaceuticals, INC. | $34.82 | 2022 | |
| Insmed, INC. | $30.45 | 2019-2025 | Brinsupri, Arikayce |
| Electromed, INC. | $24.61 | 2025 | Smartvest |
| Philips North America LLC | $21.48 | 2024 | (Ck7) Extended Holter |
| Idorsia Pharmaceuticals US INC | $20.90 | 2023 | Quviviq |
| 3b Medical, INC. | $20.21 | 2025 | Luna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.96 | 2019 | |
| Viatris Specialty LLC | $15.09 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Babb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.